CNCE 0.00 Concert Pharmaceuticals, Inc.
| Range: | 2.72-8.55 | Vol Avg: | 2542039 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.52 | Cap: | 0.40B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Feb 13 2014 | Empoloyees: | 64 | ||
| CUSIP: | 206022105 | CIK: | 0001367920 | ISIN: | US2060221056 | Country: | US |
| CEO: | Dr. Roger D. Tung Ph.D. | Website: | https://www.concertpharma.com | ||||
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow